Bayer shares surged over 7% after the U.S. Supreme Court agreed to review a key Roundup lawsuit appeal. The case questions whether federal pesticide law preempts state-level failure-to-warn claims, challenging a Missouri verdict that awarded $1.25 million to a plaintiff. Investors hope the high court's intervention could finally ease the long-running litigation overhang.

The core dispute centers on EPA authority. Bayer argues that allowing state lawsuits undermines federal regulators, who have repeatedly concluded glyphosate isn't likely carcinogenic. The U.S. Solicitor General backs this position, warning that jury verdicts could override scientific determinations. This legal battle stems from Bayer's $63 billion Monsanto acquisition, which brought thousands of lawsuits.

Kepler Cheuvreux sees a high chance of a favorable ruling by mid-2026, which would remove a major financial burden and valuation cap. Goldman Sachs estimates a positive Supreme Court decision could lift Bayer's shares 10-25%. With 60,000 cases still pending, a definitive ruling would fundamentally reshape Bayer's risk profile and investor sentiment.